KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Equivalents (2017 - 2026)

Amneal Pharmaceuticals has reported Cash & Equivalents over the past 9 years, most recently at $28.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 266.57% year-over-year to $28.8 million; the TTM value through Dec 2025 reached $28.8 million, up 266.57%, while the annual FY2025 figure was $28.8 million, 266.57% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $28.8 million at Amneal Pharmaceuticals, down from $34.7 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $278.3 million in Q2 2021 and troughed at $3.7 million in Q1 2021.
  • A 5-year average of $55.0 million and a median of $9.4 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 4214.64% in 2021 and later crashed 97.77% in 2022.
  • Year by year, Cash & Equivalents stood at $247.8 million in 2021, then plummeted by 96.27% to $9.3 million in 2022, then fell by 18.23% to $7.6 million in 2023, then rose by 4.01% to $7.9 million in 2024, then skyrocketed by 266.57% to $28.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for AMRX at $28.8 million in Q4 2025, $34.7 million in Q3 2025, and $9.6 million in Q2 2025.